Mitra Soltani, Mohammad Javad Hosseinzadeh-Attar, Mahsa Rezaei, Elham Alipoor, Ali Vasheghani-Farahani, Mehdi Yaseri, Seyed Mahdi Rezayat
Journal: Trials 2024;25(1):515
PMID: 39085864
Coronary slow flow phenomenon (CSFP) occurs when blood moves slowly through small heart vessels despite no visible blockages. It may be linked to issues with blood vessel function, oxidative stress, inflammation, or metabolic imbalances. This study examined whether nano-curcumin supplementation could improve cardiometabolic risk factors, quality of life, and depression in CSFP patients. In this randomised, double-blind, placebo-controlled trial, 50 overweight or obese adults (BMI 25–40 kg/m²), aged 35–70 years, with CSFP were assigned to receive either nano-curcumin (80 mg/day) or a placebo for 12 weeks. Results showed that while nano-curcumin did not significantly reduce high-sensitivity C-reactive protein (CRP) or visfatin [a novel adipokine which is abundantly expressed in visceral fats] levels, it helped prevent worsening of fasting blood glucose (FBG) and glycated haemoglobin compared to the placebo group. Additionally, participants who took nano-curcumin experienced significant improvements in physical and psychological quality of life and depressive symptoms. The authors concluded that 12 weeks of nano-curcumin supplementation may enhance well-being and stabilise blood sugar levels in CSFP patients, though it had no significant impact on CRP or visfatin levels.
BACKGROUND
Extensive evidence has suggested the cardio-protective properties of the polyphenol curcumin. The aim of this study was to investigate the effects of a highly bioavailable curcumin supplement on cardiometabolic risk factors, health-related quality of life, and depression in patients with coronary slow flow phenomenon (CSFP).
METHODS
This randomized double-blind placebo-controlled clinical trial was conducted in 42 patients with CSFP (age 35-70 years, 25 ≤ body mass index < 40 kg/m). Patients received either 80 mg/day nano-curcumin or placebo for 12 weeks. Serum levels of visfatin, high-sensitivity C-reactive protein (hs-CRP), and glycemic indices were measured before and after the intervention. The short form 36-item quality of life (SF-36) and Beck's Depression Inventory-II (BDI-II) questionnaires were assessed, as well.
RESULTS
No significant improvements were observed in circulating hs-CRP and visfatin following the intervention. A significant increase was observed in pre- to post-fasting blood glucose (- 0.9 ± 12.2 vs. 7.7 ± 12.4 mg/dl, p = 0.02) and hemoglobin A1C (- 0.1 ± 0.8 vs. 0.5 ± 0.8%, p = 0.04) levels, in the placebo compared with the intervention group. Physical (8.2 ± 8.1 vs. - 1.2 ± 6.5, p < 0.001) and mental (6.8 ± 11.8 vs. - 1.1 ± 10.4, p = 0.02) component summary scores were significantly improved in the nano-curcumin than the placebo group. Additionally, the number of patients with lower degrees of depression was significantly better in the intervention than the placebo group following the supplementation (p = 0.046).
CONCLUSION
Curcumin supplementation prevented deterioration of glycemic control and improved physical and psychological quality of life and depression in patients with CSFP.
TRIAL REGISTRATION
Iranian Registry of Clinical Trials (IRCT20131125015536N8), June 19, 2019.
© 2024. The Author(s).
Full Text Sources:
Medical:
Miscellaneous:
Research Materials:
© Copyright 2026, Nutrition Evidence
NED wishes to thank the following organisations for their support:
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.